![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1759276
ÁßÁõ ÇÏÁöÇãÇ÷ ½ÃÀå : ¼¼°è ¹× Áö¿ªº° - ºÐ¼®°ú ¿¹Ãø(2025-2035³â)Critical Limb Ischemia Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035 |
ÁßÁõ ÇÏÁöÇãÇ÷Àº ¸»Ãʵ¿¸ÆÁúȯ(PAD)ÀÇ ½É°¢Çϰí ÁøÇàµÈ ´Ü°è·Î, »çÁö(ÀϹÝÀûÀ¸·Î ´Ù¸®¿Í ´Ù¸®)·ÎÀÇ Ç÷·ù°¡ ÇöÀúÇÏ°Ô °¨¼ÒµÈ »óÅÂÀÔ´Ï´Ù.
ÁßÁõ ÇÏÁöÇãÇ÷Àº µ¿¸ÆÀÌ ½ÉÇÏ°Ô Á¼¾ÆÁö°Å³ª ¸·Èù °æ¿ì, º¸Åë µ¿¸Æ°æÈ·Î ÀÎÇØ µ¿¸Æ¿¡ Áö¹æ Ä§Âø¹°À̳ª ÇöóÅ©°¡ ½×¿© Ç÷·ù°¡ Á¦ÇÑµÉ ¶§ ¹ß»ýÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ç÷¾× ¼øÈ¯ÀÇ °¨¼Ò´Â Á¶Á÷¿¡¼ »ê¼Ò¿Í Çʼö ¿µ¾ç¼Ò¸¦ »©¾Ñ¾Æ ½ÉÇÑ ÅëÁõ, Ä¡À¯µÇÁö ¾Ê´Â ±Ë¾ç, ±«Àú¸¦ À¯¹ßÇÏ°í °æ¿ì¿¡ µû¶ó¼´Â Àý´ÜÀÌ ÇÊ¿äÇÑ °æ¿ìµµ ÀÖ½À´Ï´Ù.
ÁßÁõ ÇÏÁöÇãÇ÷Àº »ç¸Á·ü°ú Àå¾ÖÀÇ À§ÇèÀÌ ³ô°í, ¸¸¼ºÀûÀÎ ÈÞ½Ä ½Ã ÅëÁõ, Ä¡À¯µÇÁö ¾Ê´Â »óó ¶Ç´Â ¿µÇâÀ» ¹ÞÀº »çÁöÀÇ Á¶Á÷ »ç¸êÀ» °æÇèÇÑ »ç¶÷¿¡°Ô¼ ÈçÈ÷ Áø´ÜµË´Ï´Ù. ÀÌ ÁúȯÀº ´ç´¢º´, °íÇ÷¾Ð, Èí¿¬, ºñ¸¸°ú °°Àº À§Çè ¿äÀÎÀ» °¡Áø »ç¶÷¿¡°Ô¼ °¡Àå ÈçÇÏ°Ô ³ªÅ¸³³´Ï´Ù. Ä¡·á´Â ÀϹÝÀûÀ¸·Î ³»°úÀû °ü¸®, Àúħ½ÀÀû ½Ã¼ú(Ç÷°ü ¼ºÇü¼úÀ̳ª ½ºÅÙÆ® »ðÀÔ¼ú µî), ¿Ü°úÀû °³ÀÔ, ±×¸®°í °æ¿ì¿¡ µû¶ó¼´Â Ç÷·ù¸¦ °³¼±ÇÏ°í »çÁö¸¦ º¸Á¸Çϱâ À§ÇÑ Àç»ý ¿ä¹ýÀ» º´ÇàÇÕ´Ï´Ù. Àý´Ü°ú °°Àº ½É°¢ÇÑ ÇÕº´ÁõÀ» ÇÇÇϱâ À§Çؼ´Â Á¶±â Áø´Ü°ú °³ÀÔÀÌ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.
ÁßÁõ ÇÏÁöÇãÇ÷ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â ´ç´¢º´, °íÇ÷¾Ð, ºñ¸¸, Èí¿¬°ú °°Àº À§Çè ¿ä¼ÒÀÇ À¯º´·ü Áõ°¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀº ¸»Ãʵ¿¸ÆÁúȯ(PAD)ÀÇ ¹ßº´ °¡´É¼ºÀ» Å©°Ô Áõ°¡½Ã۰í, Á¦¶§ Ä¡·áÇÏÁö ¾ÊÀ¸¸é ÁßÁõ ÇÏÁöÇãÇ÷·Î ÁøÇàµÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À§Çè ¿äÀÎÀÌ Àü ¼¼°èÀûÀ¸·Î Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó ÁßÁõ ÇÏÁöÇãÇ÷ÀÇ ¹ß»ý·üµµ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ¿¡ µû¶ó È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ³ë³âÃþÀº ÁßÁõ ÇÏÁöÇãÇ÷ ¹ßº´ À§ÇèÀÌ ³ô±â ¶§¹®¿¡ °í·Éȵµ ½ÃÀå °³Ã´ÀÇ Áß¿äÇÑ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÁßÁõ ÇãÇ÷ Áø´ÜÀ» ¹Þ´Â ȯÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó Ç÷·ù¸¦ °³¼±ÇÏ°í »çÁö °á¼ÕÀ» ¿¹¹æÇϱâ À§ÇÑ ÃÖ¼Òħ½ÀÀû ½Ã¼ú(Ç÷°ü¼ºÇü¼ú, ½ºÅÙÆ®»ðÀÔ¼ú, Á×Á¾ÀýÁ¦¼ú µî)°ú Àç»ýÄ¡·á µî ÷´Ü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌó·³ ÁßÁõ ÇÏÁöÇãÇ÷ÀÇ ºÎ´ãÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ »õ·Î¿î Ä¡·á¹ý °³¹ßÀ» ÃËÁøÇÏ°í ½ÃÀåÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù.
ÁßÁõ ÇÏÁöÇãÇ÷ ½ÃÀåÀÇ ¼ºÀå¿¡µµ ºÒ±¸Çϰí, ¸î °¡Áö °úÁ¦°¡ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ Ç÷°ü¼ºÇü¼ú, ½ºÅÙÆ®»ðÀÔ¼ú, Á×Á¾ÀýÁ¦¼ú°ú °°Àº ÃÖ¼Òħ½ÀÀû Ä¡·á¿Í Áٱ⼼Æ÷ Ä¡·á¿Í °°Àº Àç»ýÄ¡·á°¡ ´ëÇ¥ÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ý¿¡´Â ¸¹Àº ÀÚ±ÝÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹À¸¸ç, ƯÈ÷ ÁßÀú¼Òµæ ±¹°¡³ª Á¾ÇÕÀûÀÎ º¸ÇèÀÌ Àû¿ëµÇÁö ¾Ê´Â ȯÀڵ鿡°Ô´Â Á¢±ÙÇϱ⠾î·Á¿î Ä¡·á¹ýÀÔ´Ï´Ù. ¶ÇÇÑ, ÁßÁõ ÇÏÁöÇãÇ÷ ȯÀÚ´Â °æ°ú °üÂû, Åõ¾à, ±âÀúÁúȯ(´ç´¢, °íÇ÷¾Ð µî)ÀÇ Áö¼ÓÀûÀÎ °ü¸® µî Àå±âÀûÀÎ Ä¡·á°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ ÀÇ·á½Ã½ºÅÛÀÇ ºñ¿ë ºÎ´ãÀÌ ´õ¿í Ä¿Áý´Ï´Ù. ÀÌ·¯ÇÑ °æÁ¦Àû À庮Àº Ä¡·áÀÇ Áö¿¬À̳ª ºÒÃæºÐÇÑ Ä¡·á·Î À̾îÁ® ±Ã±ØÀûÀ¸·Î ȯÀÚÀÇ ¿¹ÈÄ¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. °æÁ¦Àû ºÎ´ãÀÇ ¹®Á¦´Â ¿©ÀüÈ÷ ÁßÁõ ÇÏÁöÇãÇ÷ Ä¡·áÀÇ º¸±ÞÀ» °¡·Î¸·´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù.
¼¼°è ÁßÁõ ÇÏÁöÇãÇ÷ ½ÃÀåÀº °æÀïÀÌ Ä¡¿Çϸç, ¿©·¯ ÁÖ¿ä ±â¾÷ÀÌ ±â¼ú Çõ½Å°ú ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, Boston Scientific Corporation Inc. Bayer AG, Cytori Therapeutics, Inc., AstraZeneca, Novartis AG, Hemostemix Inc. °³¹ß ¹× »ó¾÷ÈÀÇ ÃÖÀü¼±¿¡ ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷Àº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí Àý´ÜÀÇ Çʿ伺À» ÁÙÀ̱â À§ÇÑ ÃÖ¼Òħ½ÀÀû Ä¡·á, Àç»ýÄ¡·á, ¾à¹° Ä¡·á, Çõ½ÅÀûÀÎ ÀÇ·á±â±âÀÇ ¹ßÀüÀ¸·Î Å« ÁøÀüÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ¿¬±¸ °³¹ß, Àü·«Àû ÆÄÆ®³Ê½Ê, ½ÅÈï ½ÃÀå Á¢±Ù¼º È®´ë¿¡ ´ëÇÑ ÁýÁßÀº ÁßÁõ ÇÏÁöÇãÇ÷ Ä¡·á ½ÃÀåÀÇ ¼¼°è ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼¼ºÐÈ
¼¼ºÐÈ 1: Áö¿ªº°
¼¼°è ÁßÁõ ÇÏÁöÇãÇ÷ ½ÃÀåÀº ÁßÁõ ÇÏÁöÇãÇ÷ÀÇ Áø´Ü, Ä¡·á ¹× °ü¸® ¹æ¹ýÀ» À籸¼ºÇÏ´Â »õ·Î¿î Æ®·»µå¿¡ ÈûÀÔ¾î Å« º¯È¸¦ ¸ÂÀÌÇϰí ÀÖ½À´Ï´Ù. Ç÷°ü¼ºÇü¼ú, ½ºÅÙÆ®»ðÀÔ¼ú, Á׻󵿸ÆÀýÁ¦¼úÀ» Æ÷ÇÔÇÑ ÃÖ¼Òħ½ÀÀû ½Ã¼úÀÇ »ç¿ë Áõ°¡¿Í °°Àº ÁÖ¿ä Æ®·»µå´Â ±âÁ¸ ¼ö¼ú¿¡ ºñÇØ ȸº¹ ½Ã°£ ´ÜÃà, ÇÕº´Áõ ¹ß»ý·ü °¨¼Ò, ȯÀÚ ¿¹ÈÄ °³¼± µîÀÇ ÀåÁ¡À¸·Î ÀÎÇØ ´õ¿í º¸Æíȵǰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áٱ⼼Æ÷ Ä¡·á¿Í À¯ÀüÀÚ Ä¡·á¸¦ Æ÷ÇÔÇÑ Àç»ýÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ´Ü¼øÈ÷ Áõ»óÀ» °ü¸®ÇÏ´Â °Í»Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ½Å»ýÀ» ÃËÁøÇϰí ȯºÎÀÇ Ç÷·ù¸¦ °³¼±ÇÏ¿© Àå±âÀûÀÎ ÇØ°áÃ¥À» Á¦°øÇÒ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.
ÀÌ·¯ÇÑ º¯È¿¡ ±â¿©Çϰí ÀÖ´Â ¶Ç ´Ù¸¥ Æ®·»µå´Â Á¤¹ÐÀÇ·áÀÇ ÅëÇÕÀÔ´Ï´Ù. Á¤¹ÐÀÇ·á´Â À¯ÀüÀÚ ¹× ¹ÙÀÌ¿À¸¶Ä¿ µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î ȯÀÚ °³°³ÀÎÇÁ·ÎÆÄÀÏ¿¡ ¸ÂÃß¾î Ä¡·á¸¦ ÇÏ´Â °ÍÀ¸·Î, º¸´Ù È¿°úÀûÀÌ°í ¸ÂÃã Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ, ºñħ½ÀÀû ¿µ»óÁø´Ü ±â¼ú ¹× ÷´Ü Ç÷°üÁ¶¿µ¼ú°ú °°Àº Áø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î CLIÀÇ Á¶±â ¹ß°ßÀÌ °¡´ÉÇØÁ® ±«Àú³ª Àý´Ü°ú °°Àº ´õ ½É°¢ÇÑ ´Ü°è·Î ÁøÇàµÇ´Â °ÍÀ» ¿¹¹æÇϱâ À§ÇØ º¸´Ù Àû½Ã¿¡ °³ÀÔÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.
¼¼°èÀûÀ¸·Î °í·ÉÈ¿Í CLIÀÇ À§Çè ¿äÀÎÀÎ ´ç´¢º´, °íÇ÷¾Ð, ºñ¸¸°ú °°Àº ¸¸¼º Áúȯ Áõ°¡·Î ÀÎÇØ Çõ½ÅÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Á¦¾àȸ»ç ¹× ÀÇ·á±â±â Á¦Á¶¾÷üµéÀº Áõ°¡ÇÏ´Â ¼ö¿ä¸¦ ÃæÁ·½Ã۱â À§ÇØ »õ·Î¿î Ä¡·á¹ý, ¾à¹° ¹× ±â±â °³¹ß¿¡ Á¡Á¡ ´õ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ÁßÁõ ÇÏÁöÇãÇ÷ÀÇ ÀÓ»óÀû °ü¸®¸¦ º¯È½Ãų »Ó¸¸ ¾Æ´Ï¶ó, ÇコÄÉ¾î ºÐ¾ßÀÇ ±âÁ¸ ±â¾÷ ¹× ½Å»ý ±â¾÷ ¸ðµÎ¿¡°Ô »õ·Î¿î ½ÃÀå ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.
¼¼°èÀÇ ÁßÁõ ÇÏÁöÇãÇ÷ ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÃâ ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
Critical Limb Ischemia is a severe, advanced stage of peripheral artery disease (PAD), a condition in which there is a significant reduction in blood flow to the extremities, typically the legs and feet. critical limb ischemia occurs when the arteries become severely narrowed or blocked, usually due to atherosclerosis, where fatty deposits or plaque accumulate in the arteries, restricting the blood flow. This reduced circulation deprives the tissues of oxygen and essential nutrients, leading to severe pain, non-healing ulcers, gangrene, and, in some cases, the need for amputation.
critical limb ischemia associated with a high risk of mortality and disability, and it is typically diagnosed in individuals who experience chronic rest pain, wounds that do not heal, or tissue death in the affected limb. The condition is most commonly seen in people with risk factors such as diabetes, hypertension, smoking, and obesity. Treatment usually involves a combination of medical management, minimally invasive procedures (like angioplasty and stenting), surgical interventions, and, in some cases, regenerative therapies to improve blood flow and preserve the affected limb. Early diagnosis and intervention are crucial to avoid severe complications, including amputation.
One of the key drivers of the Critical Limb Ischemia market is the rising prevalence of risk factors such as diabetes, hypertension, obesity, and smoking. These conditions significantly increase the likelihood of developing peripheral artery disease (PAD), which can progress to critical limb ischemia if not treated in time. As these risk factors continue to rise globally, the incidence of critical limb ischemia is also increasing, creating a greater demand for effective treatments. Additionally, the aging population is another important factor driving market growth, as older adults are at a higher risk of developing CLI. The growing number of patients diagnosed with critical limb ischemia is fueling the demand for advanced medical treatments, such as minimally invasive procedures (e.g., angioplasty, stenting, atherectomy) and regenerative therapies, to improve blood flow and prevent limb loss. This increasing burden of critical limb ischemia cases is propelling the development of new therapeutic options, thereby expanding the market.
Despite the growth of the Critical Limb Ischemia market, several challenges continue to hinder its progress. One of the primary challenges is the high cost of treatment associated with advanced critical limb ischemia therapies, particularly minimally invasive procedures like angioplasty, stenting, and atherectomy, as well as regenerative therapies such as stem cell treatments. These procedures often require significant financial investment, making them less accessible to patients, especially in low- and middle-income countries or for those without comprehensive insurance coverage. Additionally, the long-term care required for critical limb ischemia patients, including follow-up procedures, medications, and ongoing management of underlying conditions (such as diabetes and hypertension), further increases the cost burden on healthcare systems. This financial barrier can lead to delayed or inadequate treatment, which ultimately affects patient outcomes. The challenge of affordability remains one of the key factors limiting the widespread adoption of advanced critical limb ischemia therapies.
The global Critical Limb Ischemia market is highly competitive, with several leading companies driving innovation and market growth. Companies such as Boston Scientific Corporation Inc., Abbott Laboratories, Rexgenero Ltd., LimFlow SA, Cardiovascular Systems, Inc., Bayer AG, Cytori Therapeutics, Inc., AstraZeneca, Novartis AG, Hemostemix Inc., and Lisata Therapeutics are at the forefront of developing and commercializing treatment options for CLI. These companies are making significant strides in advancing minimally invasive procedures, regenerative therapies, pharmaceutical treatments, and innovative medical devices, aimed at improving patient outcomes and reducing the need for amputation. Their focus on research and development, strategic partnerships, and expanding access to new markets is further propelling the growth of the critical limb ischemia treatment market globally.
Market Segmentation:
Segmentation 1: by Region
The global Critical Limb Ischemia market is undergoing significant transformation, fueled by emerging trends that are reshaping the way critical limb ischemia is diagnosed, treated, and managed. Key trends such as the increasing use of minimally invasive procedures, including angioplasty, stenting, and atherectomy, are becoming more prevalent due to their advantages in reducing recovery times, lowering complication rates, and improving patient outcomes compared to traditional surgery. Additionally, the growing focus on regenerative medicine, including stem cell therapies and gene therapies, holds promise for not just managing symptoms but potentially offering long-term solutions by promoting angiogenesis and improving blood flow in the affected limbs.
Another trend contributing to this transformation is the integration of precision medicine, where treatments are tailored to individual patient profiles based on genetic and biomarker data, allowing for more effective and personalized care. Furthermore, advancements in diagnostic technologies, such as non-invasive imaging techniques and advanced angiography, are enabling earlier detection of CLI, allowing for more timely interventions that can prevent the progression to more severe stages, such as gangrene and amputation.
The global aging population and the rise in chronic conditions such as diabetes, hypertension, and obesity, all of which are risk factors for CLI, are driving the demand for innovative treatment options. In response, pharmaceutical companies and medical device manufacturers are increasingly investing in the development of new therapies, drugs, and devices to meet the growing need. These trends are not only transforming the clinical management of critical limb ischemia but also creating new market opportunities for both established players and emerging companies in the healthcare sector.
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note